New asthma drug shows promise in early trial

NCT ID NCT05008965

Recruiting now Disease control Sponsor: Oneness Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new drug, FB825, can help adults with moderate-to-severe allergic asthma. About 100 participants will receive either FB825 or a placebo. The main goal is to see if FB825 reduces asthma attacks over 24 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC ASTHMA

Contacts and locations

Locations

China Medical University Hospital
RECRUITING

Taichung, Taiwan
Far Eastern Memorial Hospital
RECRUITING

New Taipei City, Taiwan
Kaohsiung Chang Gung Medical Foundation
RECRUITING

Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITING

Kaohsiung City, Taiwan
Linkou Chang Gung Memorial Hospital
RECRUITING

Taipei, Taiwan
MacKay Memorial Hospital
RECRUITING

Taipei, Taiwan
Ministry of Health and Welfare Shuang-Ho Hospital
RECRUITING

Taipei, Taiwan
National Cheng Kung University Hospital
RECRUITING

Tainan, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
Taichung Venterans General Hospital
RECRUITING

Taichung, Taiwan
Taipei Medical University Hospital
RECRUITING

Taipei, Taiwan
Taipei Municipal Wanfang Hospital
RECRUITING

Taipei, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.